Overview
- Adjusted fourth-quarter earnings were $2.71 per share on revenue of $16.62 billion, topping Wall Street forecasts.
- AbbVie projected 2026 adjusted EPS of $14.37 to $14.57, above consensus estimates.
- Skyrizi sales rose 32.5% to $5.01 billion and beat expectations, while Rinvoq grew 29.5% to $2.37 billion and slightly missed.
- Humira revenue fell about 26% to roughly $1.25 billion but exceeded projections, and Botox Cosmetic sales grew to $717 million for the first increase since Q3 2024.
- Oncology revenue declined 2.5% and aesthetics fell 1.2% operationally, and shares dropped after the report as analysts cited filler softness and broader segment pressure; AbbVie has spent over $20 billion on acquisitions and plans about $10 billion more, including four new U.S. plants.